provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.- Your healthcare provider should show you how to use Zepbound before you use it for the first time.Review these questions with your healthcare provider: Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting ...

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology SAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine and the co-inventor of Anixa's CAR-T technology, will be a keynote speaker ...

SAN BERNARDINO, Calif., Feb. 23, 2026 /PRNewswire/ -- Locksley Resources Limited (ASX: LKY, OTCQX: LKYRF and LKYLY-ADR) announced the company has commenced diamond drilling at the high-grade Desert Antimony Mine (DAM), located within the company's Mojave Project in California. ...

PLYMOUTH, Mich., Feb. 23, 2026 /PRNewswire/ -- Adient (NYSE: ADNT), a global leader in automotive seating, today announced its latest breakthrough innovation, Sculpted Soft Trim. ...

International Tower Hill Mines to Give Updated Presentation at BMO Global Metals, Mining & Critical Minerals Conference on February 25th and Extends Webcast Invitation [Accessibility Statement] Skip NavigationVANCOUVER, BC, Feb. 23, 2026 /PRNewswire/ - International Tower Hill Mines Ltd. (the "Company", "ITH") - (TSX: ITH) (NYSE American: THM) today announced the Company will be presenting at BMO's 35th annual Global Metals, Mining & Critical Minerals Conference in Hollywood, Florida on February 25, 2026.Jo ...

Beacon Financial Corporation Announces Debut of Beacon Bank [Accessibility Statement] Skip NavigationOne of 100 largest banks in the United StatesBOSTON, Feb. 23, 2026 /PRNewswire/ -- [Beacon Financial Corporation](NYSE: BBT) (the "Company") today announced the successful combination of four storied financial institutions under one new brand, [Beacon Bank](the "Bank"), one of the 100 largest banks in the United States.Continue ReadingBeacon Bank has more than 145 branches and commercial centers across New E ...

Marpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform Expansion [Accessibility Statement] Skip NavigationNew Client Momentum Highlights Rapid Adoption of Marpai's Disruptive, Scalable Healthcare Platform Positioned to Drive Exponential Revenue Growth and Long-Term Shareholder ValueTAMPA, Fla., Feb. 23, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administ ...

Core Insights - QYOU Media has been recognized as a TikTok Agency Partner, highlighting its expertise in creator marketing and ability to help brands succeed on the platform [1][1] - The partnership allows QYOU to assist brands in building and optimizing high-performing TikTok campaigns, leveraging its proven track record [1][1] - QYOU's approach integrates creator marketing with media, delivering a unified strategy based on TikTok's best practices [1][1] Company Achievements - QYOU has partnered with major organizations such as Paramount Pictures, Kraft Heinz, Disney, and Activision, showcasing its strong track record on TikTok [1][1] - The company has received multiple accolades for its campaigns, including awards from the Telly Awards, Webby Awards, Shorty Awards, and Digiday Content Marketing Awards [1][1] - Recent campaigns recognized include "Smile 2" and "A Quiet Place: Day One" from Paramount Pictures, and "Assassin's Creed Mirage" from Ubisoft, demonstrating QYOU's effectiveness in various categories [1][1] Strategic Developments - QYOU is formalizing and expanding its media practice to enhance the distribution and amplification of creator-led content on TikTok [1][1] - The company is investing in dedicated media expertise and scalable solutions that complement its creator-first foundation [1][1] - The partnership with TikTok positions QYOU to play a significant role in shaping modern creator marketing as brands increasingly turn to TikTok for engagement [1][1]

Core Viewpoint - Aethlon Medical, Inc. is set to present at the Emerging Growth Conference on February 25, 2026, highlighting its focus on developing medical products for cancer and life-threatening infectious diseases [1] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, specializing in the development of the Hemopurifier, which targets pathogenic substances in biological fluids [1] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, addressing unmet needs in oncology and infectious diseases [1] Product Details - The Hemopurifier has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard therapies and for addressing life-threatening viruses [1] - The device operates extracorporeally with a blood pump, utilizing plasma separation, size exclusion, and affinity binding to target mannose-rich surfaces on EVs and viruses [1] Conference Information - The Emerging Growth Conference provides a platform for public companies to present their innovations and engage with investors, featuring a live interactive format [1] - Aethlon's CEO and CFO will participate in a fireside chat and answer questions from attendees, with an archived webcast available for those unable to attend live [1]

Core Viewpoint - TransCode Therapeutics has published a manuscript detailing a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells, enhancing drug delivery imaging capabilities [1]. Group 1: Research and Development - The published study in the journal Molecular Imaging and Biology describes a template-driven RIG-I agonist strategy that selectively activates RIG-I signaling in tumor cells by utilizing overexpressed oncogenic microRNAs, such as miRNA-21, as assembly templates [1]. - This new approach aims to address challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery [1]. - The findings suggest a method to engage innate immune pathways directly within tumor cells while minimizing systemic toxicity, potentially advancing RIG-I-based immunotherapy towards clinical relevance [1]. Group 2: Clinical Trials and Therapeutic Candidates - TransCode's TTX delivery platform, which is currently under evaluation in clinical trials, is expected to enhance the translational feasibility of this immunotherapy approach [1]. - The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis [1]. - TransCode's portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells [1].